
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
ข้อมูลล่าสุด
US$38.30
+US$0.90 · +2.41%
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
ราคาปิดก่อนหน้า
US$38.30
+US$0.90 · +2.41%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
ช่วงราคารายวัน
ปัจจุบัน US$38.30
ช่วง 52 สัปดาห์
ปัจจุบัน US$38.30
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
87
มูลค่าน่าสนใจมาก
ความเชื่อมั่น
41
ผสม
ความเสี่ยง
57
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
27
กำลังอ่อนตัว
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
ช่วงราคารายวัน
ปัจจุบัน US$38.30
ช่วง 52 สัปดาห์
ปัจจุบัน US$38.30
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2026 | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 |
|---|---|---|---|---|---|
| รายได้ | 1.52B USD | 1.3B USD | 1.02B USD | 977.89M USD | 942.26M USD |
| ต้นทุนสินค้าขาย | 1.01B USD | 896.27M USD | 704.59M USD | 679.65M USD | 656.86M USD |
| กำไรขั้นต้น | 511.71M USD | 399.94M USD | 313.09M USD | 298.24M USD | 285.4M USD |
| การขาย ทั่วไป และธุรการ | 312.5M USD | 289.48M USD | 259.78M USD | 226.39M USD | 206.41M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 312.5M USD | 289.48M USD | 259.78M USD | 226.39M USD | 206.41M USD |
| รายได้ดอกเบี้ย | 1.46M USD | 2.62M USD | 4.47M USD | 3.36M USD | 816K USD |
| ดอกเบี้ยจ่าย | 47.6M USD | 33.25M USD | 21.97M USD | 17.95M USD | 12.1M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 51.51M USD | 45.61M USD | 36.18M USD | 34.01M USD | 32.71M USD |
| รายได้จากการดำเนินงาน | 198.44M USD | 110.47M USD | 53.32M USD | 71.85M USD | 78.99M USD |
| รายได้สุทธิ | 99.72M USD | 48.26M USD | 2.42M USD | 32.61M USD | 49.18M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 11 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$28.00
โอกาสปรับลง 26.89%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard Morningstar Total Stock Market ETFVTI24.89M0.00%2.3T USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM20.97M0.03%78.74B USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF9.25M0.01%95.4B USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO7.3M0.05%13.92B USD0.24%US$356.78+0.94%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM7.28M0.05%15.84B USD0.03%US$53.45+0.17%
Dimensional - US Small Cap ETFDFAS6.07M0.02%33.87B USD0.31%US$78.35+0.32%
State Street SPDR S&P Pharmaceuticals ETFXPH5.78M1.25%461.57M USD0.35%US$64.65+1.60%
State Street SPDR S&P 600 Small Cap Growth ETFSLYG4.63M0.10%4.78B USD0.15%US$108.57+0.70%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Dimensional - US Small Cap ETFDFAS
State Street SPDR S&P Pharmaceuticals ETFXPH
State Street SPDR S&P 600 Small Cap Growth ETFSLYGเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน